Skip to main content
Erschienen in: Medical Oncology 4/2010

01.12.2010 | Original Paper

mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis

verfasst von: Quan Zhou, Zhansheng Deng, Yong Zhu, Haitao Long, Shaoxian Zhang, Jiali Zhao

Erschienen in: Medical Oncology | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells’ survival and proliferation. However, its roles in osteosarcoma, which is one of the most rapidly growing sarcomas, remain unknown. This study investigated for the first time the correlation between the mTOR/p70S6K signal transduction pathway in human osteosarcoma and patients’ prognosis. The expression patterns of mTOR and p70S6K in paraffin-embedded specimens gathered from 65 patients with primary osteosarcoma were detected by the method of immunohistochemistry using antibodies against mTOR and p70S6K. Kaplan–Meier survival and Cox regression analyses were performed to evaluate the prognosis of patients. Immunostaining revealed that the mTOR/p70S6K signal transduction pathway is activated in human osteosarcoma. Additionally, positive expression of mTOR and p70S6K proteins was significantly correlated with surgical stage, metastasis pattern and percentage of dead cells of osteosarcoma. Moreover, in univariate analysis, surgical stage, metastasis pattern and percentage of dead cells, mTOR and p70S6K expression showed significant influence on overall survival (OS) and disease-free survival (DFS). In multivariate analysis, surgical stage (IIA vs. IIB/III), metastasis pattern (without vs. with), percentage of dead cells (≥90 vs. <90%), mTOR expression pattern (negative vs. positive) and p70S6K expression pattern (negative vs. positive) were significant for DFS and OS. Our results demonstrate the correlation of mTOR and p70S6K expression patterns with the oncological progression of osteosarcoma patients, suggesting the prognostic significance of the mTOR/p70S6K signal transduction pathway in osteosarcoma patients, which may lay a foundation for making further investigations on the mTOR/p70S6K signal transduction pathway as a potential target for osteosarcoma therapy.
Literatur
1.
Zurück zum Zitat Longhi A, Errani C, De Paolis M. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006;32:423–36.PubMedCrossRef Longhi A, Errani C, De Paolis M. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006;32:423–36.PubMedCrossRef
2.
Zurück zum Zitat Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006;6:1075–85.PubMedCrossRef Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006;6:1075–85.PubMedCrossRef
3.
Zurück zum Zitat Ek ETH, Ojaimi J, Kitagawa Y, Choong PFM. Outcome of patients with osteosarcoma over 40 years of age: is angiogenesis a marker of survival? Int Semin Surg Oncol. 2006;3:7–18.PubMedCrossRef Ek ETH, Ojaimi J, Kitagawa Y, Choong PFM. Outcome of patients with osteosarcoma over 40 years of age: is angiogenesis a marker of survival? Int Semin Surg Oncol. 2006;3:7–18.PubMedCrossRef
4.
Zurück zum Zitat Huang J, Zhu B, Lu L, Lian Z, Wang Y, Yang X, et al. The expression of novel gene URG4 in osteosarcoma: correlation with patients’ prognosis. Pathology. 2009;41:149–54.PubMedCrossRef Huang J, Zhu B, Lu L, Lian Z, Wang Y, Yang X, et al. The expression of novel gene URG4 in osteosarcoma: correlation with patients’ prognosis. Pathology. 2009;41:149–54.PubMedCrossRef
6.
Zurück zum Zitat Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, Asami S, et al. Survivin as a prognostic factor for osteosarcoma patient. Acta Histochem Cytochem. 2006;39:95–100.PubMedCrossRef Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, Asami S, et al. Survivin as a prognostic factor for osteosarcoma patient. Acta Histochem Cytochem. 2006;39:95–100.PubMedCrossRef
7.
Zurück zum Zitat Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2005;37:19–24.PubMedCrossRef Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2005;37:19–24.PubMedCrossRef
8.
Zurück zum Zitat Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med. 2005;11:353–61.PubMedCrossRef Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med. 2005;11:353–61.PubMedCrossRef
9.
Zurück zum Zitat Martin DE, Hall MN. The expanding TOR signaling network. Curr Opin Cell Biol. 2005;17:158–66.PubMedCrossRef Martin DE, Hall MN. The expanding TOR signaling network. Curr Opin Cell Biol. 2005;17:158–66.PubMedCrossRef
10.
Zurück zum Zitat Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol. 2005;56:47–60.PubMedCrossRef Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol. 2005;56:47–60.PubMedCrossRef
11.
Zurück zum Zitat Couch FJ, et al. Localization of PS6 K to chromosomal region 17q23 and determination of its amplification in breast cancer. Cancer Res. 1999;59:1408–11.PubMed Couch FJ, et al. Localization of PS6 K to chromosomal region 17q23 and determination of its amplification in breast cancer. Cancer Res. 1999;59:1408–11.PubMed
12.
Zurück zum Zitat Liu L, et al. Rapamycin inhibits cell motility by suppression of mTOR mediated S6K1 and 4EBP1 pathways. Oncogene. 2006;25:7029–40.PubMedCrossRef Liu L, et al. Rapamycin inhibits cell motility by suppression of mTOR mediated S6K1 and 4EBP1 pathways. Oncogene. 2006;25:7029–40.PubMedCrossRef
13.
Zurück zum Zitat Bärlund M, et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst. 2000;92:1252–9.PubMedCrossRef Bärlund M, et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst. 2000;92:1252–9.PubMedCrossRef
14.
Zurück zum Zitat Heinonen H, Nieminen A, Saarela M, Kallioniemi A, Klefström J, Hautaniemi S, et al. Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer. BMC Genomics. 2008;9:348–59.PubMedCrossRef Heinonen H, Nieminen A, Saarela M, Kallioniemi A, Klefström J, Hautaniemi S, et al. Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer. BMC Genomics. 2008;9:348–59.PubMedCrossRef
15.
Zurück zum Zitat Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–20.PubMed Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–20.PubMed
16.
Zurück zum Zitat Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy-study COSS 80. J Cancer Res Clin Oncol. 1983;106(Suppl):21–4.PubMedCrossRef Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy-study COSS 80. J Cancer Res Clin Oncol. 1983;106(Suppl):21–4.PubMedCrossRef
17.
Zurück zum Zitat Pantuck AJ, Seligson DB, Klatte T. Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer. 2007;109:2257–67.PubMedCrossRef Pantuck AJ, Seligson DB, Klatte T. Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer. 2007;109:2257–67.PubMedCrossRef
18.
Zurück zum Zitat Kreuter M, Bieker R, Bielack SS. Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res. 2004;10:8531–7.PubMedCrossRef Kreuter M, Bieker R, Bielack SS. Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res. 2004;10:8531–7.PubMedCrossRef
19.
Zurück zum Zitat Kaya M, Wada T, Kawaguchi S. Increased pretherapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer. 2002;86:864–9.PubMedCrossRef Kaya M, Wada T, Kawaguchi S. Increased pretherapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer. 2002;86:864–9.PubMedCrossRef
20.
Zurück zum Zitat Workman P. Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem Soc Trans. 2004;32:393–6.PubMedCrossRef Workman P. Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem Soc Trans. 2004;32:393–6.PubMedCrossRef
21.
Zurück zum Zitat Granville CA, Memmot RM, Gills JJ, Dennis PA. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res. 2006;12:679–89.PubMedCrossRef Granville CA, Memmot RM, Gills JJ, Dennis PA. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res. 2006;12:679–89.PubMedCrossRef
22.
Zurück zum Zitat Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science. 2001;294:1942–5.PubMedCrossRef Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science. 2001;294:1942–5.PubMedCrossRef
23.
Zurück zum Zitat Mungamuri SK, Yang XH, Thor AD, Somasundaram K. Survival signaling by notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res. 2006;66:4715–24.PubMedCrossRef Mungamuri SK, Yang XH, Thor AD, Somasundaram K. Survival signaling by notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res. 2006;66:4715–24.PubMedCrossRef
24.
Zurück zum Zitat Majumder PK, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004;10:594–601.PubMedCrossRef Majumder PK, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004;10:594–601.PubMedCrossRef
25.
Zurück zum Zitat Morgensztern D, McLeod HL. Mcleod. PI3 K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005;16:797–803.PubMedCrossRef Morgensztern D, McLeod HL. Mcleod. PI3 K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005;16:797–803.PubMedCrossRef
26.
Zurück zum Zitat Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA. 2001;98:9666–70.PubMedCrossRef Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA. 2001;98:9666–70.PubMedCrossRef
27.
Zurück zum Zitat Beevers CS, Li F, Liu L, Huang S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer. 2006;119:757–64.PubMedCrossRef Beevers CS, Li F, Liu L, Huang S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer. 2006;119:757–64.PubMedCrossRef
28.
Zurück zum Zitat Hou G, Xue L, Lu Z, Fan T, Tian F, Xue Y. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett. 2007;253:236–48.PubMedCrossRef Hou G, Xue L, Lu Z, Fan T, Tian F, Xue Y. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett. 2007;253:236–48.PubMedCrossRef
Metadaten
Titel
mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis
verfasst von
Quan Zhou
Zhansheng Deng
Yong Zhu
Haitao Long
Shaoxian Zhang
Jiali Zhao
Publikationsdatum
01.12.2010
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2010
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9365-y

Weitere Artikel der Ausgabe 4/2010

Medical Oncology 4/2010 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.